Advair (salmeterol xinafoate/fluticasone propionate)

pCPA File Number: 20736

Negotiation Status:

Concluded with an LOI

Indication(s):

Chronic Obstructive Pulmonary Disease (COPD) and Asthma

Sponsor/Manufacturer:

GlaxoSmithKline Inc.

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2014-10-06

Negotiation Process Concluded:

2015-02-03